Literature DB >> 17564952

Ginkgo biloba extract improves coronary blood flow in patients with coronary artery disease: role of endothelium-dependent vasodilation.

Yuzhou Wu1, Shuqin Li, Wei Cui, Xiuguang Zu, Fengfei Wang, Jun Du.   

Abstract

Ginkgo biloba extract (GBE) has well-documented cardioprotective effects on coronary flow and positive effects on vasodilation through endothelium-derived nitric oxide in experimental animals, but these impacts in patients with coronary artery disease (CAD) have not yet been investigated. We designed this study to test the effects of GBE on distal left anterior descending coronary artery (LAD) blood flow and endothelium-dependent brachial artery flow-mediated dilation (FMD) in patients with CAD. Eighty CAD patients were randomly assigned to either GBE or saline (control) groups. LAD blood flow and brachial artery FMD were measured non-invasively using high-resolution ultrasound before and after intravenous administration of GBE or saline. GBE significantly increased LAD blood flow in maximal diastolic peak velocity (MDPV), maximal systolic peak velocity (MSPV) and diastolic time velocity integral (DTVI) compared with the control group (16.14 +/- 10.93 % vs. 0.28 +/- 2.14 %, 9.14 +/- 8.23 % vs. 0.79 +/- 2.56 %, and 15.23 +/- 7.28 % vs. 0.42 +/- 2.43 %, respectively, p < 0.01). Brachial artery FMD was also increased by 69.75 % (from 3.95 +/- 1.49 % to 6.55 +/- 2.51 %, p < 0.01). A linear correlation was found between the percentage changes in MDPV, MSPV, or DTVI of LAD blood flow and the percentage change in brachial artery FMD following treatment with GBE (r = 0.612, 0.486, or 0.521, respectively, p < 0.01). In summary, our data demonstrate that GBE treatment in CAD patients leads to an increase of LAD blood flow in MDPV, MSPV and DTVI, and the increase response might relate to the improved endothelium-dependent vasodilatory capacity. CAD: coronary artery disease DTVI: diastolic time velocity integral FMD: flow-mediated dilation GBE: GINKGO BILOBA extract LAD: distal left anterior descending coronary artery MDPV: maximal diastolic peak velocity MSPV: maximal systolic peak velocity NO: nitric oxide TTDE: transthoracic Doppler echocardiography.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17564952     DOI: 10.1055/s-2007-981536

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  6 in total

1.  Systemic and cerebral exposure to and pharmacokinetics of flavonols and terpene lactones after dosing standardized Ginkgo biloba leaf extracts to rats via different routes of administration.

Authors:  Feng Chen; Li Li; Fang Xu; Yan Sun; Feifei Du; Xutao Ma; Chenchun Zhong; Xiuxue Li; Fengqing Wang; Nating Zhang; Chuan Li
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

2.  Platelet nitric oxide signaling system in patients with coronary artery disease.

Authors:  Mahdi Garelnabi; Vinod Gupta; Venkatesan Mallika; Jayashree Bhattacharjee
Journal:  Ann Vasc Dis       Date:  2011-06-02

3.  Nitric oxide-mediated coronary flow regulation in patients with coronary artery disease: recent advances.

Authors:  Noboru Toda; Shinichi Tanabe; Sadanobu Nakanishi
Journal:  Int J Angiol       Date:  2011-09

4.  Comparative pharmacokinetics of a proliposome formulation of Ginkgo biloba extract and Ginaton in rats by a sensitive ultra performance liquid chromatography-tandem mass spectrometry method.

Authors:  Bin Zheng; Gaoyang Xing; Ye Bi; Guodong Yan; Jing Wang; Yingkun Cheng; Yan Liu; Muhammad Aqeel Ashraf; Jing Xie
Journal:  Saudi J Biol Sci       Date:  2015-09-07       Impact factor: 4.219

5.  Multi-compound and drug-combination pharmacokinetic research on Chinese herbal medicines.

Authors:  Chuan Li; Wei-Wei Jia; Jun-Ling Yang; Chen Cheng; Olajide E Olaleye
Journal:  Acta Pharmacol Sin       Date:  2022-09-16       Impact factor: 7.169

Review 6.  Integrative Therapies and Cardiovascular Disease in the Breast Cancer Population: A Review, Part 1.

Authors:  Khara Lucius; Kristen Trukova
Journal:  Integr Med (Encinitas)       Date:  2015-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.